{"cluster": 36, "subcluster": 5, "abstract_summ": "In view of dysregulated immune response, cytokine storm and inflammation-induced severe lung damage in severely ill COVID-19 patients, we propose that CD4+CD25+FoxP3+ regulatory T cell-based therapies could be considered for the patient management.COVID patients in ICU present a high mortality rate and immunoprofiling reveals heterogeneous IFN-\u03b12 production with about 20% of critically-ill patients unable to produce IFN-\u03b12, highlighting the immune response heterogeneity and opening avenues for targeted therapies.We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.We discuss approaches to decrease the morbidity and mortality in patients with COVID-19 by repurposing existing drugs previously developed for cancer therapy.Early reports suggest that tocilizumab, an IL6 receptor-blocking antibody used to manage toxicities associated with chimeric antigen receptor T-cell therapy, may help control cytokine storms in people infected with COVID-19.", "title_summ": "Cytokine Storm Drugs Move from CAR T to COVID-19.TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor FedratinibHarnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19Potential of regulatory T cell-based therapies in the management of severe COVID-19Type I IFN immunoprofiling in COVID-19 patients", "title_abstract_phrases": "Potential of regulatory T cell-based therapies in the management of severe COVID-19In view of dysregulated immune response, cytokine storm and inflammation-induced severe lung damage in severely ill COVID-19 patients, we propose that CD4+CD25+FoxP3+ regulatory T cell-based therapies could be considered for the patient management.We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.Type I IFN immunoprofiling in COVID-19 patientsCOVID patients in ICU present a high mortality rate and immunoprofiling reveals heterogeneous IFN-\u03b12 production with about 20% of critically-ill patients unable to produce IFN-\u03b12, highlighting the immune response heterogeneity and opening avenues for targeted therapies.Cytokine Storm Drugs Move from CAR T to COVID-19.Early reports suggest that tocilizumab, an IL6 receptor-blocking antibody used to manage toxicities associated with chimeric antigen receptor T-cell therapy, may help control cytokine storms in people infected with COVID-19.Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19Cytokine release and macrophage activation contribute to immunopathology after SARS-CoV-2 infection."}